Navigation Links
Complete revascularization improves outcomes for CAD patients

A 3-year, retrospective study by cardiologists from the Minneapolis Heart Institute Foundation and the University of Minnesota determined that 28.8% of patients with significant coronary artery disease (CAD) who did not undergo complete revascularization had a higher mortality rate than patients completely revascularized. Results of this study appear in the May issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions.

The research team led by Timothy Henry, M.D., FSCAI, reviewed angiographs and clinical data from 493 patients treated at the Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis, between July 2005 and August 2005. Patients were categorized based on angiographic results and initial treatment: (1) normal coronaries, (2) CAD <70%, (3) CAD >70% with complete revascularization (CR) by PCI or CABG, (4) CAD >70% with partial revascularization (PR) by PCI or CABG, (5) CAD >70% without revascularization treated with medical therapy, and (6) CAD >70% with no revascularization options despite optimal medical therapy. PCI or percutaneous coronary intervention is commonly known as angioplasty and is a common intervention used to treat CAD. CABG or coronary artery bypass grafting is another procedure where blood vessels from another part of the body (the graft) are transplanted to reroute blood around the blocked artery.

In the current study, the research team determined the prevalence of treatment options for groups 1-6 (noted above) was 14.8%, 19.5%, 36.9%, 12.8%, 9.3% and 6.7%, respectively. Researchers also found that 3-year mortality increased with angiographic severity of CAD with groups 1-6 having a 2.7%, 6.3%, 8.2%, 12.7%, 17.4%, and 15.2%, rate respectively. "Our results showed patients with incomplete revascularization (groups 4-6) had a risk of mortality more than double that of completely revascularized patients," said Dr. Henry. After 3 years, study participants with incomplete revascularization had a 14.8% mortality risk compared with 6.6% in patients with complete revascularization.

Additionally, the team found that patients with incomplete revascularization were older, more often male, and more likely to have hypertension, diabetes, peripheral arterial disease, previous history of CAD including heart attack, PCI, and CABG. Many of the patients in the "no option" group had more than one reason for no further revascularization including chronic total occlusions (70%), diffuse disease (46%), and collateral dependent perfusion (42%). The "no-option" patients had an annual mortality of 3-5%, similar to patients with incomplete revascularization. Researchers speculate the reasons for improved morality could be associated with advances in medical therapy for patients with CAD.

Coronary artery disease is caused by a buildup of plaque (cholesterol deposits) in the arteries supplying blood to the heart. Overtime, plaque buildup can lead to angina (pectoris), a common symptom of CAD that causes severe chest pain due to the inadequate supply of oxygenated blood to the heart. Experts estimate that 16.8 million Americans are living with CAD and 9.8 million have angina. "This growing patient population is in need of novel therapeutic strategies aimed at improving not only mortality but also quality of life," Dr. Henry concluded.


Contact: Dawn Peters

Related medicine news :

1. Woman with MS Summits Everest and Completes the Seven Summits
2. Kineta Awarded NIH Grant to Complete Preclinical Studies on Type 1 Diabetes / Multiple Sclerosis Drug Candidate
3. Phybridge Inc. Joins the Cisco Developer Network and Completes Cisco Interoperability Verification Testing
4. The European Medicines Agency Completes Validation Stage for InterMunes Marketing Authorization Application for pirfenidone
5. Pelosi: Today, We Have the Opportunity to Complete the Great Unfinished Business of Our Society and Pass Health Insurance Reform for All Americans
6. SAN SnapShot Backup for VMWare - Does Your Backup Always Completes In Seconds, Is 1000x Faster and Costs 90% Less?
7. International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc.
8. Anthera Pharmaceuticals Completes Initial Public Offering
9. Kaiser Permanente Completes Electronic Health Record Implementation
10. Solta Medical Completes Acquisition of Aesthera Corporation
11. Neovasc Completes Final Tranche of $1.537 Million Non-Brokered Private Placement
Post Your Comments:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
(Date:6/24/2016)... ... 24, 2016 , ... Today, MTI-GlobalStem, a provider of optimized ... difficult to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing ... is a complete system for culturing and transfecting human pluripotent stem cells ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: